专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0240996A8 DIFFERENTIAL GENE EXPRESSION IN SPECIFIC REGIONS OF THE BRAIN IN NEURODEGENERATIVE DISEASES 审中-公开
标题翻译：脑中特异性区域差异基因表达在神经损伤疾病中的表达
公开(公告)号：WO0240996A8
公开(公告)日：2003-02-13
申请号：PCT/US0146699
申请日：2001-11-08
申请人： MITOKOR , HWANG JUNG-JOO , BECKER DAVID K , DAVIS ROBERT E
发明人： HWANG JUNG-JOO , BECKER DAVID K , DAVIS ROBERT E
IPC分类号： G01N33/50 , G01N33/68
CPC分类号： G01N33/6896 , C07K16/18 , C07K2317/34 , G01N33/5011 , G01N33/5014
摘要： The present invention provides methods and compositions for screening assays for compounds that alter mitochondrial function, and in particular that alter apoptosis, based on the observations that expression of the transcription factor FREAC-2 is up-regulated in Alzheimer's disease and that induction of FREAC-2 expression in a cell results in apoptosis. The invention thus provides methods for identifying agents that alter mitochondrial function by determining the activity of reducing or enhancing apoptosis that follows the induced expression of FREAC-2, useful, for example, in treatment of neurodegenerative diseases ( e.g., Alzheimer's) and/or of diseases of inappropriate cell proliferation or survival ( e.g., cancer). The present invention also includes methods of identifying pharmaceutical/ molecular targets for compounds that alter mitochondrial function ( e.g., by altering apoptosis).
摘要翻译：本发明提供了用于筛选针对改变线粒体功能的化合物的测定方法和组合物，特别是基于在阿尔茨海默氏病中上调转录因子FREAC-2的表达和FREAC- 2在细胞中的表达导致细胞凋亡。因此，本发明提供了通过确定减少或增强FREAC-2诱导表达后的凋亡的活性来鉴定改变线粒体功能的药物的方法，例如可用于治疗神经变性疾病（例如， >阿尔茨海默病）和/或不适当的细胞增殖或存活的疾病（例如，癌症）。本发明还包括鉴定改变线粒体功能（例如通过改变细胞凋亡）的化合物的药物/分子靶标的方法。

2. 发明申请

WO0070099A3 DIFFERENTIAL GENE EXPRESSION IN SPECIFIC REGIONS OF THE BRAIN IN NEURODEGENERATIVE DISEASES 审中-公开
标题翻译：脑中特异性区域差异基因表达在神经损伤疾病中的表达
公开(公告)号：WO0070099A3
公开(公告)日：2002-04-04
申请号：PCT/US0013951
申请日：2000-05-19
申请人： MITOKOR , HWANG JUNG JOO , BECKER K DAVID , DAVIS ROBERT E
发明人： HWANG JUNG-JOO , BECKER K DAVID , DAVIS ROBERT E
IPC分类号： G01N33/50 , A61K31/7088 , A61K35/76 , A61K38/00 , A61K38/22 , A61K45/00 , A61K48/00 , A61P25/00 , A61P25/28 , A61P31/04 , A61P31/12 , A61P35/00 , C12N5/10 , C12N15/09 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/53 , G01N33/566
CPC分类号： C12Q1/6883 , C12Q1/6851 , C12Q2600/158
摘要： The present invention provides nucleic acid molecules that can function as PCR primers for the detection of contactin mRNA in a sample. Such nucleic acid molecules can be labeled and can be provided in a kit. The present invention also includes a method of detecting the presence of a neurodegenerative disease such as multiple sclerosis, including providing a sample from a patient and measuring the amount of contactin protein or contactin mRNA expressed in the sample. The present invention further provides a method for identifying which patents having a neurodegenerative disease are likely to respond to a treatment for a neurodegenerative disease. The present invention further includes compositions of matter that include an isolated cell or a cell in culture that expresses an increased or decreased amount of contactin as compared to a control cell. The present invention also includes a method for screening compounds for the activity of reducing or enhancing the expression of contactin and compositions or compounds, including pharmaceutical compositions, identified by this method. Also included are methods of treating a neurodegenerative disease using such compositions or compounds. The present invention also includes methods of identifying pharmaceutical targets for compounds that modulate contactin expression or activity and targets identified by such methods.
摘要翻译：本发明提供可用作检测样品中的接合蛋白mRNA的PCR引物的核酸分子。这样的核酸分子可以被标记，并且可以在试剂盒中提供。本发明还包括检测神经变性疾病如多发性硬化的存在的方法，包括从患者提供样品并测量样品中表达的接触蛋白或接触蛋白mRNA的量。本发明还提供了一种用于鉴定具有神经变性疾病的哪些专利可能对神经变性疾病的治疗有反应的方法。本发明还包括与对照细胞相比，包括分离的细胞或培养物中与表达增加或减少量的接触蛋白的细胞的物质组合物。本发明还包括用于筛选化合物以减少或增强接触蛋白和通过该方法鉴定的组合物或化合物（包括药物组合物）表达的活性的方法。还包括使用这些组合物或化合物治疗神经变性疾病的方法。本发明还包括鉴定调节接触蛋白表达或活性的化合物的药物靶标和通过这些方法鉴定的靶标的方法。

3. 发明申请

WO2005061711A1 A POLYNUCLEOTIDE ASSOCIATED WITH A TYPE II DIABETES MELLITUS COMPRISING SINGLE NUCLEOTIDE POLYMORPHISM, MICROARRAY AND DIAGNOSTIC KIT COMPRISING THE SAME AND METHOD FOR ANALYZING POLYNUCLEOTIDE USING THE SAME 审中-公开
标题翻译：与包含单核多聚核苷酸的微型糖尿病和诊断试剂盒的II型糖尿病相关的多核苷酸和使用其分析多核苷酸的方法
公开(公告)号：WO2005061711A1
公开(公告)日：2005-07-07
申请号：PCT/KR2004/003441
申请日：2004-12-24
申请人： SAMSUNG ELECTRONICS CO., LTD. , LEE, Kyu-Sang , KIM, Jae-Heup , PARK, Kyung-Hee , LEE, Yeon-Su , SON, Ok-Kyoung , CHO, Ji-Young , PARK, Yeon-A , HONG, Sung-Woo , HWANG, Jung-Joo , JEON, Hyo-Jeong
发明人： LEE, Kyu-Sang , KIM, Jae-Heup , PARK, Kyung-Hee , LEE, Yeon-Su , SON, Ok-Kyoung , CHO, Ji-Young , PARK, Yeon-A , HONG, Sung-Woo , HWANG, Jung-Joo , JEON, Hyo-Jeong
IPC分类号： C12N15/11
CPC分类号： C12Q1/6883 , C12Q1/6837 , C12Q2600/156
摘要： Provided is a polynucleotide for diagnosis or treatment of type II diabetes mellitus, including at least 10 contiguous nucleotides of a nucleotide sequence selected from the group consisting of nucleotide sequences of SEQ ID NOS: 1-80 and including a nucleotide at position 101 of the nucleotide sequence, or a complementary polynucleotide thereof.
摘要翻译：提供了用于诊断或治疗II型糖尿病的多核苷酸，包括选自SEQ ID NO：1-80的核苷酸序列的核苷酸序列的至少10个连续核苷酸，并且包含核苷酸的位置101的核苷酸序列或其互补多核苷酸。

4. 发明申请

WO0240996A9 DIFFERENTIAL GENE EXPRESSION IN SPECIFIC REGIONS OF THE BRAIN IN NEURODEGENERATIVE DISEASES 审中-公开
标题翻译：脑中特异性区域差异基因表达在神经损伤疾病中的表达
公开(公告)号：WO0240996A9
公开(公告)日：2003-10-02
申请号：PCT/US0146699
申请日：2001-11-08
申请人： MITOKOR , HWANG JUNG-JOO , BECKER DAVID K , DAVIS ROBERT E
发明人： HWANG JUNG-JOO , BECKER DAVID K , DAVIS ROBERT E
IPC分类号： G01N33/50 , G01N33/68 , C12Q1/68 , A61K48/00
CPC分类号： G01N33/6896 , C07K16/18 , C07K2317/34 , G01N33/5011 , G01N33/5014
摘要： The present invention provides methods and compositions for screening assays for compounds that alter mitochondrial function, and in particular that alter apoptosis, based on the observations that expression of the transcription factor FREAC-2 is up-regulated in Alzheimer's disease and that induction of FREAC-2 expression in a cell results in apoptosis. The invention thus provides methods for identifying agents that alter mitochondrial function by determining the activity of reducing or enhancing apoptosis that follows the induced expression of FREAC-2, useful, for example, in treatment of neurodegenerative diseases (e.g., Alzheimer's) and/or of diseases of inappropriate cell proliferation or survival (e.g., cancer). The present invention also includes methods of identifying pharmaceutical/ molecular targets for compounds that alter mitochondrial function (e.g., by altering apoptosis).
摘要翻译：本发明提供了用于筛选针对改变线粒体功能的化合物的测定方法和组合物，特别是基于在阿尔茨海默氏病中上调转录因子FREAC-2的表达和FREAC- 2在细胞中的表达导致细胞凋亡。因此，本发明提供了通过确定减少或增强FREAC-2诱导表达后的凋亡的活性来鉴定改变线粒体功能的药物的方法，例如可用于治疗神经变性疾病（例如阿尔茨海默病）和/或不适当的细胞增殖或存活的疾病（如癌症）。本发明还包括鉴定改变线粒体功能（例如通过改变细胞凋亡）的化合物的药物/分子靶标的方法。

5. 发明申请

WO0240996A3 DIFFERENTIAL GENE EXPRESSION IN SPECIFIC REGIONS OF THE BRAIN IN NEURODEGENERATIVE DISEASES 审中-公开
标题翻译：神经退行性疾病脑内特定区域的差异基因表达
公开(公告)号：WO0240996A3
公开(公告)日：2003-07-10
申请号：PCT/US0146699
申请日：2001-11-08
申请人： MITOKOR , HWANG JUNG-JOO , BECKER DAVID K , DAVIS ROBERT E
发明人： HWANG JUNG-JOO , BECKER DAVID K , DAVIS ROBERT E
IPC分类号： G01N33/50 , G01N33/68 , C12Q1/68 , A61K48/00
CPC分类号： G01N33/6896 , C07K16/18 , C07K2317/34 , G01N33/5011 , G01N33/5014
摘要： The present invention provides methods and compositions for screening assays for compounds that alter mitochondrial function, and in particular that alter apoptosis, based on the observations that expression of the transcription factor FREAC-2 is up-regulated in Alzheimer's disease and that induction of FREAC-2 expression in a cell results in apoptosis. The invention thus provides methods for identifying agents that alter mitochondrial function by determining the activity of reducing or enhancing apoptosis that follows the induced expression of FREAC-2, useful, for example, in treatment of neurodegenerative diseases (e.g., Alzheimer's) and/or of diseases of inappropriate cell proliferation or survival (e.g., cancer). The present invention also includes methods of identifying pharmaceutical/ molecular targets for compounds that alter mitochondrial function (e.g., by altering apoptosis).
摘要翻译：本发明提供了用于筛选测定化合物的方法和组合物，所述化合物改变线粒体功能，特别是改变细胞凋亡，基于观察到转录因子FREAC-2的表达在阿尔茨海默病中上调，并且诱导FREAC- 2在细胞中的表达导致细胞凋亡。因此，本发明提供了通过确定在诱导表达FREAC-2之后降低或增强细胞凋亡的活性来鉴定改变线粒体功能的试剂的方法，其可用于例如治疗神经退行性疾病（例如阿尔茨海默病）和/或不适当的细胞增殖或存活的疾病（例如癌症）。本发明还包括鉴定改变线粒体功能（例如通过改变细胞凋亡）的化合物的药物/分子靶的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式